Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04510467
  4. Details
NCT04510467 Clinical Trial

Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Covid19 Clinical Trial

— MentCovid19RMD  

Official title:
Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT04510467
Other study ID # 2020_75
Secondary ID 2020-A02058-31
Status Terminated
Phase
First received
Last updated
Start date January 20, 2021
Est. completion date May 19, 2022

Study information
Verified date January 2023
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Recruitment information / eligibility
Status Terminated
Enrollment 296
Est. completion date May 19, 2022
Est. primary completion date May 19, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patient case: - Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease - With confirmed COVID-19 infection (at least one month prior to study inclusion) - Study information given to the patient - Patient affiliated to social security Patient control: - Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease. - Not having had a confirmed COVID-19 infection - Study information given to the patient - Patient affiliated to social security Exclusion Criteria: - Opposition to participation in the study by the patient and/or his legal representative - Adult patient not able to understand the implications and rules of the study - Protected adults under guardianship or curatorship

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Hop Claude Huriez Chu Lille Lille

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Lille FAI²R (Auto-immune and auto-inflammatory rare diseases French network)

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection
Secondary Severity of PTSD depending on whether or not autoimmune patients have experienced COVID at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3